Genetic Variant May Reduce Children's Response to Common Asthma Treatment

A new study in the Journal of Allergy and Clinical Immunology reveals that children carrying a variant in the SERPINE1 gene—present in about 60% of the population—may experience reduced effectiveness from mepolizumab, a biologic medication used to treat asthma flares. This genetic variant appears to trigger increased inflammation in response to the drug, potentially limiting its therapeutic benefit. Understanding this genetic predisposition could help healthcare providers identify which children may need alternative or adjusted asthma management strategies. This finding underscores the growing importance of personalized medicine in treating pediatric asthma and optimizing treatment outcomes for affected children.